|
|||||
|
|
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma |
|
| Authors: | Kirkwood John M Bastholt Lars Robert Caroline Sosman Jeff Larkin James Hersey Peter Middleton Mark Cantarini Mireille Zazulina Victoria Kemsley Karin Dummer Reinhard |
| Affiliation: | Departments of Medicine and Dermatology, University of Pittsburgh, PA 15213, USA. KirkwoodJM@upmc.edu |
| Abstract: | |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |